For U.S. Residents Only
+|Aa|-

Indication for Renvela and Renagel

Renvela® (sevelamer carbonate) and Renagel® (sevelamer hydrochloride) are indicated for the control of serum phosphorus in patients with chronic kidney disease on dialysis.

Important Safety Information for Renvela and Renagel

  • Sevelamer is contraindicated in patients with bowel obstruction.

Click here for additional Important Safety Information.

Please see full Prescribing Information for Renvela (PDF) or full Prescribing Information for Renagel (PDF).

Have concerns about Renvela® prescription coverage?

On average, most patients pay less than $7/month for their Renvela prescription. Learn more at Renassist.com.

Renassist®: renal medication access and support

What is Renassist?

  • Renassist is the Sanofi Renal reimbursement group dedicated to providing assistance and support for patients prescribed Renvela® (sevelamer carbonate).
  • A case manager will be dedicated to you at no cost to help with your prescription coverage, access benefits, and/or apply for financial assistance.
  • Get more information at Renassist.com or call 1-800-847-0069 to speak with a case manager.

 

What support can Renassist provide?

  • Renvela® (sevelamer carbonate) prescription drug benefit verification
  • Prior authorizations facilitation
  • Patient assistance programs information
  • Medicare Part D and reimbursement education
  • Get more information at Renassist.com or call 1-800-847-0069 to speak with a case manager.

Contact a Renassist case manager now at


  • T: 1-800-847-0069

  • F: 1-877-363-6732

  • E: renassist@sanofi.com

Monday through Friday, 8:30 AM to 5:00 PM (EST)

Have concerns about Renvela® prescription coverage?

Indication for Renvela and Renagel

Renvela® (sevelamer carbonate) and Renagel® (sevelamer hydrochloride) are indicated for the control of serum phosphorus in patients with chronic kidney disease on dialysis.

Important Safety Information for Renvela and Renagel

  • Sevelamer is contraindicated in patients with bowel obstruction.
  • Caution should be exercised in patients with dysphagia, swallowing disorders, and severe gastrointestinal (GI) motility disorders, including severe constipation or major GI tract surgery.
  • Common adverse events reported with sevelamer include vomiting, nausea, diarrhea, dyspepsia, abdominal pain, flatulence, and constipation. Other events reported include pruritus, rash, fecal impaction and, less commonly, ileus, bowel obstruction, and bowel perforation.
  • Uncommon cases of difficulty swallowing the Renagel (sevelamer hydrochloride) or Renvela® (sevelamer carbonate) tablet have been reported. Caution should be exercised in these patients and consideration given to using Renvela® (sevelamer carbonate) suspension in patients with a history of difficulty swallowing.
  • Drug-drug interactions may occur with some medications and should be taken into consideration when instructing patients how to take sevelamer.
  • Serum bicarbonate and chloride levels should be monitored.
  • Follow patients for reduced vitamins D, E, and K (coagulation parameters) and folic acid levels.
  • Patients should be informed to take sevelamer with meals and to adhere to their prescribed diets.

Please see full Prescribing Information for Renvela (PDF) or full Prescribing Information for Renagel (PDF).
Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.

The health information contained herein is provided for general education purposes only. Your healthcare professional is the single best source of information regarding your health. Please consult your healthcare professional if you have any questions about your health or treatment.